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Diagnosis of gastrointestinal (GI) cytomegalovirus (CMV) disease relies on the presence of GI symptoms and
detection of CMV, mainly by immunohistochemistry (IHC), in GI biopsy specimens. Thus, in a symptomatic
patient, a positive CMV-IHC result is accepted as a diagnosis of CMV disease. However, a positive CMV-PCR in GI
tissue is considered “possible” CMV disease. Therefore, it would be very useful if, in practice, both techniques
showed equal sensitivity and reliability. This is because PCR has many practical advantages over IHC for detecting
CMV. The aim of this study was to compare quantitative PCR with IHC for the diagnosis of GI CMV disease. A total
of 186 endoscopic GI biopsy specimens from 123 patients with GI symptoms after an allogeneic stem cell trans-
plantation (allo-SCT; 2004-2017) were analyzed by IHC and PCR on 113 paraffin-embedded and 73 fresh samples.
The results were then compared. Of the patients with macroscopic lesions in the mucosa and CMV-IHC-positive
biopsy specimens (eg, “proven” CMV disease, n = 28), all but 1 were CMV-PCR positive. Of the patients without
macroscopic lesions in the mucosa and CMV-IHC-positive biopsy specimens (eg, probable CMV disease, n = 4),
only 1 was CMV-PCR positive. Eight patients had CMV-IHC-negative/CMV-PCR-positive gut biopsy specimens.
These cases fall within the current definition of possible CMV disease. In 6 of these 8 cases (75%), the viral load in
GI tissue was very high (>10,000 copies/mg). Taken together, the results from the proven and probable cases
revealed that CMV-PCR shows the same sensitivity (100%), specificity (98%), and positive (93%) and negative pre-
dictive value (100%) as CMV-IHC. Detection of CMV in fresh GI mucosa by quantitative PCR is as useful as IHC for
the diagnosis of GI CMV disease. The results show that quantitative PCR has the same sensitivity, specificity, and
positive/negative predictive value as IHC.
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Cytomegalovirus (CMV) infection and CMV disease after
allogeneic stem cell transplantation (allo-SCT) are associated
with significant morbidity. Since the introduction of pre-emp-
tive anti-CMV therapy for CMV-seropositive recipients, the
incidence of CMV disease during the first year after allo-SCThas decreased from approximately 35% to 8% to 10% [1]. Well-
known risk factors associated with CMV disease include CMV
seropositivity, development of graft-versus-host disease
(GVHD), prednisone treatment, and depletion of T cells from
the graft [2-7]. The gastrointestinal (GI) system is the organ
most frequently involved in CMV disease, usually the lower
tract. Concomitant diagnosis of GVHD and GI CMV disease is
common, but signs and symptoms of GI CMV disease (eg, diar-
rhea, vomiting, anorexia, bleeding, and abdominal pain) are
often indistinguishable from those of GI GVHD. Ulcers extend-
ing into the gut mucosa are seen upon endoscopy, but these
macroscopic findings are common to both GVHD and viral
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common GI CMV disease than GVHD, especially if the upper GI
tract is affected [10,11].
The difficulty in distinguishing between GVHD and CMV dis-
ease in clinical practice obligates for GI CMV disease diagnosis
the detection of CMV in biopsy specimens by histopathology,
culture, virus isolation, or immunohistochemistry (IHC) [12].
Detection of CMV by hematoxylin and eosin (H&E) staining of
GI tissue depends on the presence of classic CMV viral inclusions.
However, viral inclusions are often not apparent; therefore, IHC
is used by most centers to detect CMV. Thus, IHC is considered
the gold standard for CMV detection in formalin-fixed, paraffin-
embedded (FFPE) tissue [13]. However, IHC can lead to an equiv-
ocal interpretation due to atypical staining patterns. Therefore,
the value of IHC for detecting bona fide CMV infection depends
on the observer, a fact that contributes to inter- and intralabora-
tory variability. It is suggested that in such cases, molecular
methods (ie, quantitative PCR) could be complementary [14,15].
In addition, IHC for detecting inclusions in FFPE sections takes
longer (at least 48 hours) than PCR (at least 24 hours).
Current methods used to diagnose CMV disease include
DNA hybridization and PCR. Detecting CMV using molecular
methods such as quantitative PCR (qPCR) is fast, highly sensi-
tive, and more objective than IHC [16-19]. It is surprising,
therefore, that the role of qPCR for diagnosis of CMV disease
remains unclear.
New definitions of CMV disease, which were designed origi-
nally to harmonize terminology for clinical trials, can be applied
to the setting of allo-SCT in cases of pneumonia and GI CMV dis-
ease. This definition establishes 3 new categories: proven, proba-
ble, and possible CMV disease (see Methods). Of note, high viral
DNA levels detected in tissue by qPCR in a patient showing clini-
cal symptoms are defined as possible CMV disease, particularly
when a blood sample taken at the same time is negative for CMV
[20]. Due to the lack of specific studies, there is no defined
threshold for the viral load upon which a diagnosis of CMV dis-
ease (either pneumonia or GI) can be based [1,20,21,22].
Here, the hypothesis was that qPCR would have sensitivity,
positive predictive value (PPV), and negative predictive value
(NPV) at least similar to that of the current gold standard (IHC)
for detection and diagnosis of GI CMV disease. We also hypothe-
sized that by comparing the results obtained after IHC and qPCR
of GI samples, we could define a cutoff viral load in GI tissue
that would facilitate diagnosis and follow-up of GI CMV disease.METHODS
General
We analyzed data from patients with GI symptoms who received an allo-
SCT and, as a result, had an endoscopic procedure performed. Biopsy speci-
mens of GI tissue were examined by histology, IHC, and qPCR. In addition,
data obtained from electronic medical records were analyzed. The study was
carried out in 2 steps.
First, a retrospective analysis of data from patients receiving allo-SCT
between 2004 and 2009 was done. IHC results at the time of diagnosis (obtained
from medical records) and PCR results obtained from paraffin-embedded sam-
ples of the same biopsy specimens stored in the institution’s biobank were
examined. This group is referred to hereafter as “paraffin samples.”
Second, data from patients receiving allo-SCT between 2010 and 2017
were prospectively assessed. Data were collected up until 1 year post-
transplant. The results obtained by IHC and qPCR analysis of GI samples taken
during the same endoscopic procedure were analyzed. Hereafter, this group
is referred to as “fresh samples.”
For every patient, qPCR analysis of CMV in blood samples was performed
up until 180 days post-transplant; these data were included in the analysis.
At this institution, when an allo-SCT patient develops GI symptoms, stool cul-
tures are taken and tested for bacteria, fungi, or viral infections (including
Clostridium difficile, adenovirus, and rotavirus). If GI symptoms persist and
cultures are negative (results are obtained within 48-72 hours), an endo-
scopic procedure is performed.Microbiological Assessment
CMV serology (immunoglobulin G CMV) had been made in all donors and
recipients before the allo-SCT. qPCR (Q-CMV Real Time Complete Kit; Nano-
gen Advanced Diagnostics, Buttigliera, Italy) was performed to detect CMV
infection in both plasma and tissue. This was carried out in the Microbiology
Department. All patients were monitored weekly for CMV infection during
the first 6 months post-allo-SCT or while on immunosuppressive treatment.
Patients who developed GVHD or were on steroids were monitored twice a
week. Pre-emptive treatment was started when CMV DNA in blood samples
reached >1000 IU/mL. When patients were enrolled and data were analyzed,
the international conversion factor for PCR-CMV was not defined. Therefore,
analysis was based on the PCR results themselves. Data are shown with the
international conversion factor applied (value: PCR local laboratory£ 0.8).
Definitions (Ljungman et al CID, 2017 [20])
CMV infection is defined as isolation of virus or detection of viral proteins
(antigens) or CMV nucleic acid in any body fluid or tissue specimen.
GI CMV disease is subcategorized as follows: proven disease requires
upper and/or lower GI symptoms plus macroscopic mucosal lesions (ulcers,
sores, edema, or erythema), plus documented evidence of CMV in tissue
obtained by histopathology, virus isolation, rapid culture, IHC or DNA hybrid-
ization. Probable disease requires upper/lower GI symptoms plus docu-
mented evidence of CMV in tissue (using the same techniques as mentioned
above) but without macroscopic mucosal lesions. Possible disease requires
detection of high viral DNA levels by qPCR in GI tissue (in the presence of GI
symptoms), particularly when a blood sample obtained at the same time
does not contain CMV DNA.
Endoscopic Procedure
Amultiple biopsy endoscopic study was performed using an Olympus CF-
H185-L (Hamburg, Germany) endoscope. A macroscopic description of the GI
tract was recorded. Samples were taken during the endoscopic procedure
and sent to the pathology department for IHC (formol) and to the microbiol-
ogy department for microscopic and qPCR-CMV analysis (saline serum).
Immunohistochemistry
FFPE samples from multiple endoscopic biopsy specimens were examined.
At least 3 sections (each 5 mm thick) were processed. H&E was used for conven-
tional morphologic examination. IHC staining was performed using a monoclo-
nal antibody specific for CMV (1:1 dilution; Dako, Carpinteria, CA). A result was
considered positive if more than 1 cell was detected. The median time from
endoscopic biopsy to diagnosis was 72 hours (range, 48 to 120 hours).
qPCR
We analyzed a minimum of 5 cuts 5 mm thick for paraffin samples and a
minimum of 10 mg of tissue for fresh samples (recommended sample size by
manufacturer is 10 to 40 mg). A pretreatment for paraffin samples was
required before purification of DNA from tissue. The cuts were treated with
1200 mL xylene, and after vortexing and centrifugation, the supernatant was
removed. Then, 1200 mL ethanol was added, and again after vortexing and
centrifugation, the supernatant was removed. The sample preparation proce-
dure and purification of genomic DNA from paraffin-embedded tissue and
fresh tissue were performed with the EZ1 DNA Tissue Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s specifications and using the Bio-
Robot EZ1 (Qiagen). The concentration of DNA was determined by measuring
the absorbance at 260 nm in a spectrophotometer.
Plasma samples (500 mL) were extracted using the Qiagen Qiamp DNA
Mini Kit on a QiaSymphony system (Qiagen).
The extraction efficiency was verified by adding an internal control to
each sample (tissue and plasma), and an external negative control was used
to detect possible contamination.
qPCR (Q-CMV Real Time Complete Kit; Nanogen Advanced Diagnostics)
was used to detect CMV infection in plasma and tissue using a 7300 Real
Time PCR System (Applied Biosystems). Limit of detection of the DNA amplifi-
cation allows detection of the presence of 10 CMV DNA copies per PCR reac-
tion. The positive results of tissue sample were expressed as copies per
microgram of DNA [23].
A result was considered positive if more than 1000 copies/mg of DNA
were detected. The median time from endoscopic procedure to diagnosis
report was 48 hours (range, 36 to 72 hours).
Statistical Analysis
Quantitative variables were reported as the median (interquartile range)
and categorical variables as absolute numbers (percentages). The sensitivity,
specificity, and PPV/NPV of IHC and qPCR were compared. Sensitivity meas-
ures the proportion of actual positives correctly identified as such, whereas
specificity measures the proportion of actual negatives correctly identified
as such. The PPV and NPV are the proportions of positive and negative results
from diagnostic tests that are truly positive and truly negative, respectively.
The chi-square or Fisher exact test was used to compare categorical variables,
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assess continuous and quantitative parameters. The level of significance was
set at P < .05. All statistical analyses were performed using SPSS version 22.0
(SPSS, Inc, Chicago, IL).RESULTS
Between January 2004 and August 2017, 688 patients
received an allo-SCT at the Hospital Clínic of Barcelona. The
study was approved by the Ethic Committee of the Hospital
Clínic of Barcelona and conducted in accordance with the Decla-
ration of Helsinki. All patients provided informed consent. Of
the 688 patients, 123 (18%) fulfilled the following criteria: GI
symptoms, underwent an endoscopic procedure, and tissue
analyzed by both IHC and PCR. The median time from allo-SCT
to development of GI symptoms was 90 days (range, 45 to 270
days). A total of 186 GI biopsy samples were analyzed (Figure 1).
Patient demographics and transplant characteristics are
shown in Table 1.
Of the 186 samples (113 paraffin samples and 73 fresh sam-
ples) analyzed, endoscopic examination identified 88 (47%) as
having macroscopic mucosal lesions (ulcers, edema, or ery-
thema). Most of the samples, 149 (80%) (91 paraffin samples
and 58 fresh samples), belonged to the lower tract, and only
37 (20%) samples (22 paraffin samples and 15 fresh samples)
corresponded to the upper tract. GVHD was diagnosed in 32
(36%); GI CMV disease in 29 (33%), 27 (94%) of the lower and 2
(6%) of the upper tract; mycophenolate toxicity in 2 (2%); and
other infections (viral, bacteria, or fungi) in 18 (20%). Normal
mucosa was identified in the remaining 98 samples (53%). Of
these, GVHD was diagnosed in 38 (38%); GI CMV disease in 12
(12%), 11 (91%) of the lower and only 1 (9%) of the upper tract;
mycophenolate toxicity in 1 (1%); and other infections (viral,
bacteria, and fungi) in 7 (7%).
The diagnosis of GI CMV disease was done when GI symp-
toms were present together with detection of CMV (by IHC) in
the biopsy specimens. This definition was applied in both the
paraffin and fresh samples groups.
Paraffin Samples Group
In total, 113 samples from 63 patients were analyzed retro-
spectively. GI CMV disease was diagnosed in 14 patients (22%);







Both IHC and PCR Results available 
n= 63 (113 samples)
“paraffin samples group”
Figure 1. Inclusioall from the lower tract (90%). In 17 of these episodes, patients
presented with macroscopic lesions in the GI mucosa, and
CMV was detected in endoscopic biopsy specimens by IHC [16]
and/or inclusion bodies were detected by H&E [3]; therefore,
there were 17 episodes of proven CMV GI disease. In the other
3 episodes of CMV disease, patients had GI symptoms but no
macroscopic lesions in the GI tract; CMV-IHC of endoscopic
biopsy tissue was positive. These were defined as probable GI
CMV disease (n = 3).
GVHD was diagnosed in 25 patients (40%); infections other
than CMV were diagnosed in 8 patients (13%). Other diagnoses
were toxicities related to mycophenolate (1.5%) and/or radio-
therapy (1.5%) (Table 2). The remaining 14 cases (22%) had no
specific diagnosis.
At this time, PCR techniques on tissue were not available.
For this reason, there were only cases of proven and probable
CMV disease. Retrospectively, CMV-PCR was performed in the
paraffin samples as described in the Methods.
Among the proven CMV cases (n = 17), CMV-PCR was positive
in 16 (94%). However, for the 3 probable CMV cases, PCR was
negative in all of them; these PCR results were considered false
negatives. For the cases in which PCR of paraffin-embedded gut
tissue was positive, the median CMV load was 1910 copies/mg
(range, 1250 to 311,640 copies/mg). CMV-PCR in blood samples
taken at the same time was positive in 65% of cases.
There were 3 additional patients (CMV-IHC negative in the
gut) in whom CMV-PCR was positive in the endoscopic biopsy
specimens. Of these, 2 had a low viral load in the tissue (1335
and 3119 copies/mg). Both tissue results were interpreted as
false positives. One of these 3 patients had a CMV-PCR positive
and CMV-IHC negative (viral load in tissue 4089 copies/mg)
but undetectable viral load in blood (defined as possible CMV
disease according to the new definition by Ljungman et al.
[20]). In this case, endoscopy was repeated 10 days later
because symptoms persisted; endoscopy identified macro-
scopic lesions in the gut, and both CMV-IHC and CMV-PCR of
biopsy tissue were positive. Therefore, this case was finally
diagnosed as proven CMV disease. Therefore, IHC showed a
sensitivity of 95%, a specificity of 97%, a PPV of 86%, and an
NPV of 99% for GI CMV disease. PCR in the gut biopsy speci-
mens showed a sensitivity of 80%, a specificity of 97%, a PPV of
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Patients and Transplant-Related Characteristics
Characteristic Total Paraffin Fresh
Patients, No. 123 63 60
Male/Female, No. 72/51 36/27 36/24
Age, median (range), y 53 (22-68) 53 (23-65) 53 (22-68)
SCT type, No. (%)
Sibling HLA identical 59 (48) 32 (50) 27 (45)
Haplofamiliar 4 (3) 0 (0) 4 (6)
UNR matched 36 (29) 17 (27) 19 (32)
UNR mismatched 24 (20) 14 (22) 10 (17)
Conditioning regimen, No. (%)
Myeloablative 43 (35) 24 (38) 19 (32)
Cy/TBI 31 (25) 21 (33) 10 (16)
Bu/Cy 7 (5) 3 (5) 4 (7)
BEAM 4 (3) 3 (5) 1 (2)
Flu/Bu4 4 (3) 0 (0) 4 (7)
Nonmyeloablative 80 (65) 39 (62) 41 (68)
Flu/Bu3 24 (21) 7 (11) 17 (28)
Flu/Mel 34 (27) 19 (30) 15 (25)
IdaFLAG 16 (13) 10 (16) 6 (10)
Flu/TBI 8 Gy 2 (2) 0 (0) 2 (3)
Flu/TBI 2 Gy 1 (1) 0 (0) 1 (2)
Source of stem cells, No. (%)
Peripheral blood 111 (91) 57 (91) 56 (93)
Bone marrow 7 (6) 4 (6) 3 (5)
Cord blood 3 (3) 2 (3) 1 (2)
GVHD prophylaxis, No. (%)
CNI/MTX 37 (30) 24 (38) 13 (22)
CNI/mycophenolate 83 (68) 39 (62) 44 (73)
CNI (tacrolimus) 3 (2) 0 (0) 3 (5)
ATG 24 (20) 17 (27) 7 (12)
PT-Cy 11 (10) 0 (0) 11 (19)
CMV serostatus, No. (%)
High risk (D/R+) 38 (31) 20 (32) 18 (30)
Intermediate risk (D+/R+) 71 (58) 34 (54) 37 (62)
Low risk (D/R) 14 (11) 9 (14) 5 (8)
SCT indicates stem cell transplantation; UNR, unrelated; Cy, cyclophospha-
mide; TBI, total-body irradiation; Bu, busulfan; BEAM, BCNU (carmustine), eto-
poside, cytarabine, and melphalan; Flu, fludarabine; Bu4, Busulphan 4 days;
Bu3, Busulphan 3 days; Mel, melphalan; IdaFLAG, idarubicin, fludarabine,
cytarabine, and G-CSF; CNI, calcineurin inhibitor; MTX, methotrexate; ATG,
antithymocyte globulin; PT-Cy, post-transplant cyclophosphamide.
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Seventy-three samples from 60 patients were analyzed
prospectively. GI CMV disease was diagnosed in 10 patients
(16%), all from the lower tract. Of them, there were 12 episodes
where patients presented with macroscopic lesions in the gut
mucosa and IHC detected CMV in biopsy tissue (all 12 episodes
were designated proven CMV disease). One patient with noTable 2
Comparison of Results from IHC and PCR in GI Samples in CMV GI disease in the Retros
Paraffin Samples (n = 113) Retrospective Microscopic Finding
GVHD Infection
No CMV GI disease (n = 93) 39 (42) 14 (15)
CMV GI disease (n = 20) 7 (35) 0 (0)
Proven (n = 17) (symptoms, IHC+, mucosa lesions) 6 (35) 0 (0)
Probable (n = 3) (symptoms, IHC+, normal mucosa) 1 (33) 0 (0)macroscopic lesions in the gut was CMV-IHC positive (proba-
ble CMV disease). Finally, in 8 episodes, CMV-PCR of biopsy tis-
sue was positive but CMV-IHC was negative; therefore, these
were considered possible CMV disease. Of these 8 patients, 4
(50%) had macroscopic lesions in the gut. All proven, probable,
and possible cases received antiviral treatment (total of 21 epi-
sodes from 13 patients).
GVHD was diagnosed in 31 patients (52%). Other infections
were diagnosed in 20 (27%) cases, as well as toxicity related to
mycophenolate (3%), Post-transplant lymphoprolipherative
disorder (4%), and nonspecific inflammatory features (16%)
(Table 3).
CMV-PCR in tissue from proven and probable CMV disease
cases (12 and 1, respectively) was positive in all of them
(100%), with a median viral load of 184,627 copies/mg (range,
1250 to 5,483,875 copies/mg). Blood PCR was positive in 85% of
these cases. There were 8 possible CMV disease cases with a
median viral load in gut samples of 100,242 copies/mg (range,
1940 to 483,261 copies/mg); of these, 62% had a positive CMV-
PCR in blood. Of these 8 cases, 2 had a low viral load in tissue
(1940 copies/mg and 3976 copies/mg). In the first case, blood
PCR was negative and antiviral treatment was given. Of note,
3 patients with mucosal ulcers and who were CMV-IHC nega-
tive/CMV-PCR positive (possible) underwent a repeat endo-
scopic procedure 7 days later; the samples taken then were
CMV-IHC positive (proven CMV disease). Taking together all
the results, viral load in tissue was >10,000 copies/mg in 70%
(9/13) of the patients with proven/probable CMV disease and
in 75% (6/8) of the patients with possible CMV disease.
Concomitant GVHD in the gut specimen was evident in 7
proven/probable CMV disease cases and in 5 possible CMV dis-
ease cases. In 6 patients, diagnosis of both GVHD and GI CMV
disease was made at the same time (when the patient devel-
oped GI symptoms). In the remaining patients, GVHD was
diagnosed previously. The median time from GVHD diagnosis
to diagnosis of GI CMV disease was 40 days. There were no sig-
nificant differences in the median viral load in gut specimens
from proven/probable CMV disease cases with or without con-
comitant GVHD (503,841 copies/mg versus 1,847,126 copies/
mg, P = .314) in possible CMV disease cases with or without
GVHD (100,242 copies/mg versus 113,565 copies/mg, P> .99).
Coinfection was detected in a similar percentage of proven
and possible CMV disease cases (33% versus 37%, respectively).
When analyzing proven and probable CMV disease, we
found that CMV-PCR of fresh gut samples had the same sensi-
tivity (100%), specificity (98%), PPV (93%), and NPV (100%) as
CMV-IHC for the diagnosis of GI CMV disease.
DISCUSSION
CMV disease is not a common complication after allo-SCT,
but it is associated with significant morbidity and mortality. GI
tract problems are the most common presentation, almost
always restricted to the lower tract. For both novel and classi-
cal diagnostic criteria, a patient must show clinical symptomspective Analysis of the Paraffin Samples Group
s, No. (%) qPCR Tissue, No. (%) qPCR Blood, No. (%)
Other Positive Positive
3 (3) 3 (3) 8 (9)
0 (0) 16 (80) 13 (65)
0 (0) 16 (95) 9 (53)
0 (0) 0 (0) 3 (100)
Table 3
Comparison of Results from IHC and PCR in GI Samples in CMV GI Disease in the Prospective Analysis of the Fresh Samples Group
Fresh Samples (n = 73) Prospective Microscopic Findings, No. (%) qPCR Tissue, No. (%) qPCR Blood, No. (%)
GVHD Infection Other Positive Positive
No CMV GI disease (n = 52) 26 (50) 12 (23) 5 (9) 1 (2) 5 (10)
CMV GI disease (n = 13) 7 (54) 4 (31) 0 (0) 13 (100) 11 (84)
Proven (n = 12) (symptoms, IHC+, mucosa lesions) 7 (58) 4 (33) 0 (0) 12 (100) 10 (83)
Probable (n = 1) (symptoms, IHC+, normal mucosa) 0 (0) 0 (0) 0 (0) 1 (100) 1 (100)
Possible CMV disease (n = 8) (symptoms, IHC, PCR + in gut biopsy) 5 (62) 3 (37.5) 0 (0) 8 (100) 5 (62)
Table 4
Management for Treatment in Possible GI CMV Disease Based on PCR
Viral Load Tissue Viral Load Plasma Diagnosis Treatment
Any >10,000 copies/mg Any Possible CMV disease CMV disease
<10,000 copies/mg Any >1000 CMV infection Pre-emptive*
<10,000 copies/mg Undetectable Indeterminate Wait and see*
* Repeat endoscopic procedure if GI symptoms persist.
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affecting the upper/lower GI tract are indistinguishable from
those associated with GVHD. Therefore, we have to look for
other distinctive signs; this is where endoscopic biopsy can be
helpful. Some authors [10] report that macroscopic findings
such as ulcers are associated with GI CMV disease; however,
this has not been confirmed. Here, we found that 70% of
patients with GI CMV disease had ulcers, although ulcers are
more commonly associated with GVHD.
The next step toward a diagnosis is detection of CMV in tis-
sue. IHC is the gold-standard method for histopathologic diag-
nosis. The introduction of PCR as a diagnostic tool for CMV has
led to its incorporation for diagnosing GI CMV disease. Accord-
ing to the new classification, a CMV-PCR-positive tissue is con-
sidered possible CMV disease [20].
All diagnostic methods have limitations. The quality of the
sample is the main determinant of a reliable result. PCR is a
molecular method that requires DNA extraction from the sam-
ple, followed by quantification of this DNA. Automated extrac-
tion and quantification of viral DNA greatly reduce the
possibility of error and make the technique more objective
and reproducible. By contrast, IHC requires interpretation by a
pathologist, and the results can vary depending on the thick-
ness of the section; therefore, several sections are used to
reduce the impact of this limitation.
In our experience, PCR works better for fresh samples than
for paraffin-embedded samples. Formalin is not a suitable
medium for microbiologic tests, particularly if DNA analysis is
required. Moreover, DNA extraction is more difficult in the pres-
ence of paraffin, a substance that also inhibits PCR reactions.
Another limitation of PCR is deciding on an appropriate cut-
off for the viral load. Different confounding factors may influ-
ence quantification of viral DNA (eg, GVHD and/or other
infections). In our experience, the viral load during most GI
CMV disease episodes (proven, probable, and possible) was
very high. Indeed, in 70% of cases, the blood PCR result was
positive. There was no significant difference in median viral
load between those with GVHD and those without, bearing in
mind that the number of patients analyzed in this setting was
small (n = 41).
From the data obtained herein, we defined a possible
threshold for the viral load in gut specimens for the diagnosis
of possible GI CMV disease. Because in 75% of possible CMV
disease cases, the viral load in tissue was higher than >10,000
copies/mg, we suggest the following (see Table 4): Any result >10,000 copies/mg in tissue could be considered
GI CMV disease, regardless of the result of PCR in blood, and
treated as CMV disease.
 If viral load in tissue is <10,000 copies/mg and PCR-CMV in
blood is positive, it could be considered CMV infection and
pre-emptive therapy should be started. If GI symptoms per-
sist after 7 to 10 days of antiviral treatment, re-evaluate
with a new endoscopy.
 If viral load in tissue is <10,000 copies/mg and PCR-CMV in
blood is negative, we would suggest a “wait-and-see”
approach, and if gastrointestinal symptoms persist after 7
to 10 days, re-evaluate with a new endoscopy.
In summary, the data presented herein show that detection
of CMV in fresh GI mucosa using quantitative PCR has the
same sensitivity, specificity, PPV, and NPV as IHC for the diag-
nosis of proven and probable CMV disease. Therefore, PCR is as
useful and reliable as IHC for GI CMV disease diagnosis and is
faster and more objective. It is important to point out that
there is a trend of higher viral load in proven/probable versus
possible GI CMV disease, suggesting that possible CMV disease
could be an early diagnosis. In this line, note that there were 3
possible CMV disease cases that, in a second biopsy 7 days
later, developed a proven CMV disease.
This would be a step forward in clinical practice in patients
undergoing allo-SCT, as it would allow starting treatment of GI
CMV disease more promptly (with a diagnosis of possible CMV
disease) than in proven or probable CMV disease. Finally, an
attempt to define a cutoff for PCR-CMV in tissue to initiate
antiviral treatment could be 10,000 copies/mg, in view of the
results obtained. The qPCR could also be useful for monitoring
the response of the treatment and to define treatment dura-
tion. More studies are needed to confirm these findings of
CMV-PCR in tissue and to implement it in clinical practice.DECLARATION OF COMPETING INTEREST
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